CombiMatrix's Q1 Revenues Slide 9 Percent; Nasdaq Warns of Low Bid Price | GenomeWeb
NEW YORK (GenomeWeb News) — CombiMatrix today said that first-quarter revenue dropped 9 percent as R&D spending fell 22 percent and net losses shrank by 73 percent.
Total receipts for the three months ended March 31 decreased to $1.1 million from $1.2 million during the same period last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.